Seok Jung Im, Joo In Soo, Yoon Jung Han, Choi Yun Jung, Lee Phil Hyu, Huh Kyoon, Bang Oh Young
Department of Neurology, School of Medicine, Catholic University of Daegu, Korea.
Clin Neurol Neurosurg. 2008 Feb;110(2):110-6. doi: 10.1016/j.clineuro.2007.09.005. Epub 2007 Oct 26.
Aspirin resistance is one of several possible explanations for limited efficacy or treatment failure of aspirin. However, the predictors of aspirin resistance are not well known. We therefore conducted a study of laboratory-defined aspirin resistance in Korean patients with ischemic stroke and considered a wide range of factors as possible predictors.
A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included. Platelet function was assessed using the Rapid Platelet Function Assay-Aspirin (RPFA-ASA) system and the level of urinary thromboxane B2 (TX-B2). The result of the RPFA-ASA system was expressed as an aspirin reaction unit (ARU). We analyzed a wide range of factors including demographic data, stroke risk factors, and laboratory findings to identify the clinical predictors of aspirin resistance.
Eleven (12%) patients were identified as aspirin resistant by the ARU criteria. Univariate analysis showed that an older age, lower LDL cholesterol levels, and concurrent use of angiotensin converting enzyme inhibitors or receptor blockers were related to aspirin resistance by ARU criteria. Aspirin resistance by urinary TX-B2 criteria was observed in 18 (25%) patients and associated with an older age, metabolic syndrome, diabetes, cigarette smoking, and the use of angiotensin-converting enzyme inhibitors or receptor blockers. In multivariate analysis, this association lost significance by ARU criteria, and only lower fibrinogen levels were associated with increased risk by TX-B2 criteria. In addition, the stroke subtypes and the degree of atherosclerosis were not associated with aspirin resistance. The correlation between the two criteria was poor (r=-0.115, p=0.34).
Despite the comprehensive analysis of this study, we failed to identify independent predictors for laboratory-defined aspirin resistance. Additionally, little overlap was found between the two criteria with which to assess aspirin resistance.
阿司匹林抵抗是阿司匹林疗效有限或治疗失败的几种可能解释之一。然而,阿司匹林抵抗的预测因素尚不明确。因此,我们对韩国缺血性中风患者进行了一项关于实验室定义的阿司匹林抵抗的研究,并将多种因素视为可能的预测因素。
共纳入88例每日服用阿司匹林进行中风二级预防的患者。使用快速血小板功能检测 - 阿司匹林(RPFA - ASA)系统和尿血栓素B2(TX - B2)水平评估血小板功能。RPFA - ASA系统的结果以阿司匹林反应单位(ARU)表示。我们分析了包括人口统计学数据、中风危险因素和实验室检查结果在内的多种因素,以确定阿司匹林抵抗的临床预测因素。
根据ARU标准,11例(12%)患者被确定为阿司匹林抵抗。单因素分析显示,年龄较大、低密度脂蛋白胆固醇水平较低以及同时使用血管紧张素转换酶抑制剂或受体阻滞剂与根据ARU标准的阿司匹林抵抗有关。根据尿TX - B2标准,18例(25%)患者存在阿司匹林抵抗,且与年龄较大、代谢综合征、糖尿病、吸烟以及使用血管紧张素转换酶抑制剂或受体阻滞剂有关。在多因素分析中,根据ARU标准这种关联失去了显著性,而根据TX - B2标准只有较低的纤维蛋白原水平与风险增加有关。此外,中风亚型和动脉粥样硬化程度与阿司匹林抵抗无关。两种标准之间的相关性较差(r = -0.115,p = 0.34)。
尽管本研究进行了全面分析,但我们未能确定实验室定义的阿司匹林抵抗的独立预测因素。此外,评估阿司匹林抵抗的两种标准之间几乎没有重叠。